NEJM publishes results from Celgene’s REVLIMID phase III studies on MM - News-Medical.Net

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma (MM-015) This double-blind, phase III, multicenter, randomized study conducted by Celgene compared melphalan-prednisone-lenalidomide induction followed by lenalidomide ...

Lenalidomide-based Regimens for Multiple Myeloma - Med India

Treatment for multiple myeloma includes bone marrow transplantation, radiation and chemotherapy. Chemotherapy earlier included two medications, melphalan and prednisone. Later, other medications like thalidomide, bortezomib and lenalidomide were added to ...

Celgene (CELG) Unit Reports Publication of Three REVLIMID Studies in MM Patients - StreetInsider.com

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma (MM-015) This double-blind, phase III, multicenter, randomized study conducted by Celgene compared melphalan–prednisone–lenalidomide induction followed by lenalidomide maintenance ...

Delcath Announces Proposed Public Offering Of Common Stock And Warrants - Marketwatch

The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at www.delcath.com

Revlimid Delays Relapse in Multiple Myeloma - MedPage Today

In the first trial, researchers led by Antonio Palumbo, MD, of the University of Turin in Italy compared three regimens in 459 patients 65 or older: Induction with melphalan (Alkeran), prednisone, and lenalidomide, followed by lenalidomide ...

Iraqi cancer patient finds hope in India - Webindia 123

But the process was not easy. "Abdul was treated with a medicine, Melphalan, for a year and a half, which was damaging to stem cells. The only solution was bone marrow transplant. So using a different regime, we developed adequate stem cells and ...

New England Journal of Medicine Reports on Three Phase III REVLIMID(R) (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma - Marketwatch

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma (MM-015) This double-blind, phase III, multicenter, randomized study conducted by Celgene compared melphalan--prednisone--lenalidomide induction followed by lenalidomide ...

Onyx Pharmaceuticals Announces Data Presentations at 48th American Society of Clinical Oncology Annual Meeting - CNBC

Poster #15 Abstract #8035 Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma Dr. Brigitte Kolb, University Hospital, Nantes, France Sunday, June 3, 2012 Oral presentation: 8:00 AM - 8:15 ...

Research and Markets: Amyloidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Boston Globe

The current off-label drugs prescribed to treat AL amyloidosis, such as melphalan, cyclophosphamide, vincristine, dexamethasone, prednisolone and Thalomid (thalidomide) and doxorubicin, lack efficacy and safety. As a result, the median survival ...

ZYTIGA® (abiraterone acetate) Data to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting - Stockhouse

About VELCADE ® (bortezomib) [3] VELCADE ® (bortezomib) is a first-in-class proteasome inhibitor approved in the EU for use in combination with melphalan and prednisone in previously untreated patients with multiple myeloma (i.e. the front line setting ...